Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15

被引：83

作者：

Lehmann-Che, Jacqueline ^{[1
,2
,3
]}

Hamy, Anne-Sophie ^{[4
]}

Porcher, Raphael ^{[5
]}

Barritault, Marc ^{[1
,2
]}

Bouhidel, Fatiha ^{[6
]}

Habuellelah, Hanadi ^{[4
]}

Leman-Detours, Solenne ^{[4
]}

de Roquancourt, Anne ^{[6
]}

Cahen-Doidy, Laurence ^{[8
]}

Bourstyn, Edwige ^{[4
]}

de Cremoux, Patricia ^{[1
,2
,3
]}

de Bazelaire, Cedric ^{[9
]}

Albiter, Marcela ^{[9
]}

Giacchetti, Sylvie ^{[4
]}

Cuvier, Caroline ^{[4
]}

Janin, Anne ^{[6
,7
]}

Espie, Marc ^{[4
]}

de The, Hugues ^{[1
,2
,3
]}

Bertheau, Philippe ^{[3
,6
,7
]}

机构：

[1] Hop St Louis, AP HP, Biochem Lab, F-75010 Paris, France

[2] CNRS, IUH, UMR7212, INSERMU944, F-75010 Paris, France

[3] Univ Paris Diderot, Sorbonne Paris Cite, F-75010 Paris, France

[4] Hop St Louis, AP HP, Breast Dis Ctr, F-75010 Paris, France

[5] Hop St Louis, AP HP, Dept Biostat, F-75010 Paris, France

[6] Hop St Louis, AP HP, Pathol Lab, F-75010 Paris, France

[7] INSERM, UMR S728, F-75010 Paris, France

[8] Hop St Louis, AP HP, Dept Surg, F-75010 Paris, France

[9] Hop St Louis, AP HP, Dept Radiol, F-75010 Paris, France

来源：

BREAST CANCER RESEARCH | 2013年 / 15卷 / 03期

关键词：

cancer; breast carcinoma; molecular apocrine; estrogen receptor; HER2; GCDFP15; triple negative; basal-like; ANDROGEN RECEPTOR; PIK3CA MUTATIONS; EXPRESSION; CLASSIFICATION; IDENTIFICATION; CARCINOMAS; PROGNOSIS; ALPHA; ER;

D O I：

10.1186/bcr3421

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Molecular apocrine (MA) tumors are estrogen receptor (ER) negative breast cancers characterized by androgen receptor (AR) expression. We analyzed a group of 58 transcriptionally defined MA tumors and proposed a new tool to identify these tumors. Methods: We performed quantitative reverse transcription PCR (qRT-PCR) for ESR1, AR, FOXA1 and AR-related genes, and immunohistochemistry (IHC) for ER, PR, Human Epidermal Growth Factor Receptor 2 (HER2), CK5/6, CK17, EGFR, Ki67, AR, FOXA1 and GCDFP15 and we analyzed clinical features. Results: MA tumors were all characterized by ESR1(-) AR(+) FOXA1(+) and AR-related genes positive mRNA profile. IHC staining on these tumors showed 93% ER(-), only 58% AR(+) and 90% FOXA1(+). 67% and 57% MA tumors were HER2(3+) and GCDFP15(+), respectively. Almost all MA tumors (94%) had the IHC signature HER2(3+) or GCDFP15(+) but none of the 13 control basal-like (BL) tumors did. Clinically, MA tumors were rather aggressive, with poor prognostic factors. Conclusion: MA tumors could be better defined by their qRT-PCR-AR profile than by AR IHC. In addition, we found that HER2 or GCDFP15 protein overexpression is a sensitive and specific tool to differentiate MA from BL in the context of ER negative tumors. A composite molecular and IHC signature could, therefore, help to identify MA tumors in daily practice.

引用

页数：11

共 42 条

[1] Androgen receptor expression in estrogen receptor-negative breast cancer - Immunohistochemical, clinical, and prognostic associations [J].